400 - The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma.
Saved in:
| Title: | 400 - The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma. |
|---|---|
| Authors: | Diallo, B., Massonnet, G., El-Botty, R., Raymondie, C., Howes, C., Wilson, J., Smith, A., Roman-Roman, S., Smith, P., Davies, E., Decaudin, D., Némati, F. |
| Source: | European Journal of Cancer. Dec2016 Supplement 1, Vol. 69, pS132-S132. 1p. |
| Database: | Academic Search Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: asn DbLabel: Academic Search Ultimate An: 120140920 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: 400 - The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Diallo%2C+B%2E%22">Diallo, B.</searchLink><br /><searchLink fieldCode="AR" term="%22Massonnet%2C+G%2E%22">Massonnet, G.</searchLink><br /><searchLink fieldCode="AR" term="%22El-Botty%2C+R%2E%22">El-Botty, R.</searchLink><br /><searchLink fieldCode="AR" term="%22Raymondie%2C+C%2E%22">Raymondie, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Howes%2C+C%2E%22">Howes, C.</searchLink><br /><searchLink fieldCode="AR" term="%22Wilson%2C+J%2E%22">Wilson, J.</searchLink><br /><searchLink fieldCode="AR" term="%22Smith%2C+A%2E%22">Smith, A.</searchLink><br /><searchLink fieldCode="AR" term="%22Roman-Roman%2C+S%2E%22">Roman-Roman, S.</searchLink><br /><searchLink fieldCode="AR" term="%22Smith%2C+P%2E%22">Smith, P.</searchLink><br /><searchLink fieldCode="AR" term="%22Davies%2C+E%2E%22">Davies, E.</searchLink><br /><searchLink fieldCode="AR" term="%22Decaudin%2C+D%2E%22">Decaudin, D.</searchLink><br /><searchLink fieldCode="AR" term="%22Némati%2C+F%2E%22">Némati, F.</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22European+Journal+of+Cancer%22">European Journal of Cancer</searchLink>. Dec2016 Supplement 1, Vol. 69, pS132-S132. 1p. |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=120140920 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/S0959-8049(16)32991-4 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 1 StartPage: S132 Titles: – TitleFull: 400 - The MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) appears as an efficient targeted therapy when used in an adjuvant setting in patient-derived xenografts of uveal melanoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Diallo, B. – PersonEntity: Name: NameFull: Massonnet, G. – PersonEntity: Name: NameFull: El-Botty, R. – PersonEntity: Name: NameFull: Raymondie, C. – PersonEntity: Name: NameFull: Howes, C. – PersonEntity: Name: NameFull: Wilson, J. – PersonEntity: Name: NameFull: Smith, A. – PersonEntity: Name: NameFull: Roman-Roman, S. – PersonEntity: Name: NameFull: Smith, P. – PersonEntity: Name: NameFull: Davies, E. – PersonEntity: Name: NameFull: Decaudin, D. – PersonEntity: Name: NameFull: Némati, F. IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 12 Text: Dec2016 Supplement 1 Type: published Y: 2016 Identifiers: – Type: issn-print Value: 09598049 Numbering: – Type: volume Value: 69 Titles: – TitleFull: European Journal of Cancer Type: main |
| ResultId | 1 |
